Response to Amgen’s KRAS inhibitor declines as more patients added in NSCLC cohort

The partial response rate reported Sunday from the high dose of Amgen’s KRAS inhibitor AMG 510 had nowhere to go but down, given that the 100% PR rate seen earlier this year was from just three patients. While the metric fell farther than investors expected, the company said it may seek approval based an ongoing Phase II study, which is using the dose.

Among 13

Read the full 659 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE